<p>The Cancer Genetic Markers of Susceptibility (CGEMS) prostate cancer genome-wide association study (GWAS) included genotyping   approximately 550,000 SNPs (Phase 1A with HumanHap300 and Phase 1B HumanHap240, both from Illumina, San Diego, CA) in 1,172   prostate cancer patients and 1,157 controls of European ancestry from the Prostate, Lung, Colon and Ovarian   (PLCO, <a href="http://www.cancer.gov/prevention/plco/">http://www.cancer.gov/prevention/plco/</a>) Cancer   Screening Trial. The original analysis published in Nature Genetics [PMID: <a href="http://ncbi.nlm.nih.gov/pubmed/17401363">17401363</a>]   included 2,282 subjects. After improvement and revisions of the original analysis, 2,252 subjects were submitted to dbGaP.</p>

CGEMS Prostate Cancer GWAS - Stage 1 - PLCO

Prostatic Neoplasms study with SNP Genotypes (Array) data on dbGaP (2,252 participants)

CGEMS Prostate Cancer GWAS - Stage 1 - PLCO

Description

Applying For Access

Summary